Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Krzysztof Misiukiewicz

Research output: Contribution to journal › Article › peer-review

1542 Scopus citations

Fingerprint

Dive into the research topics of 'Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study'. Together they form a unique fingerprint.

Medicine & Life Sciences